All In Biotech

NDA 212888 · Viiv Hlthcare

Cabenuva Kit

Cabotegravir, Rilpivirine · Intramuscular

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Nov 26, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Jan 21, 2021

Approved uses

8

Original approval plus efficacy supplements

Registered trials

97

26 Phase 3, 19 recruiting

FAERS reports

6,543

1,293 serious, 123 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 26, 2025.

CABENUVA is indicated as a complete regimen for the treatment of HIV-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine [see Microbiology ( 12.4 ), Clinical Studies ( 14.1 )] . CABENUVA, a 2-drug co-packaged product of cabotegravir, an HIV-1 integrase strand transfer inhibitor (INSTI), and rilpivirine, an HIV-1 non‑nucleoside reverse transcriptase inhibitor (NNRTI), is indicated as a complete regimen for the treatment of HIV-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg to replace the current antiretroviral regimen in those who are virologically suppressed (HIV‑1 RNA <50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine. ( 1 )

Mechanism: CABENUVA contains 2 long-acting HIV-1 antiretroviral drugs, cabotegravir and rilpivirine [see Microbiology ( 12.4 )] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 16, 2026 Supplement 18 · Efficacy LetterLabel
  • Sep 20, 2024 Supplement 15 · Efficacy · priority review LetterLabel
  • Mar 29, 2022 Supplement 6 · Efficacy · priority review LetterLabel
  • Mar 29, 2022 Supplement 5 · Efficacy · priority review LetterLabel
  • Mar 23, 2022 Supplement 3 · Efficacy LetterLabel
  • Feb 7, 2022 Supplement 2 · Efficacy LetterLabel
  • Jan 31, 2022 Supplement 1 · Efficacy LetterLabel
  • Jan 21, 2021 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination · priority review NovelLetterLabelReview
2 products under this application
  • CABENUVA KIT · CABOTEGRAVIR 400MG/2ML (200MG/ML); RILPIVIRINE 600MG/2ML (300MG/ML) · SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription
  • CABENUVA KIT · CABOTEGRAVIR 600MG/3ML (200MG/ML); RILPIVIRINE 900MG/3ML (300MG/ML) · SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cabotegravir" as an intervention, any sponsor and status, largest first.

All 97 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • product dose omission issue722
  • injection site pain669
  • viral load increased514
  • off label use478
  • product use in unapproved therapeutic environment459
  • virologic failure434
  • pathogen resistance323
  • pain304
  • product complaint218
  • exposure during pregnancy208
  • injection site nodule203
  • blood hiv rna increased197

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20191
20202
2021205
2022829
20231,276
20241,500
20251,515
20261,215

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 117 on PubMed

Sponsor: GSK

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.